Updates on the Diagnosis and Treatment of Peripheral Autonomic Neuropathies

Guillaume Lamotte1 · Paola Sandroni2

Accepted: 5 October 2022 / Published online: 15 November 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

Purpose of Review Autonomic neuropathies are a complex group of disorders and result in diverse clinical manifestations that affect the cardiovascular, gastrointestinal, urogenital, and sudomotor systems. We focus this review on the diagnosis and treatment of peripheral autonomic neuropathies. We summarize the diagnostic tools and current treatment options that will help the clinician care for individuals with peripheral autonomic neuropathies.

Recent Findings Autonomic neuropathies occur often in conjunction with somatic neuropathies but they can also occur in isolation. The autonomic reflex screen is a validated tool to assess sympathetic postganglionic sudomotor, cardiovascular sympathetic noradrenergic, and cardiac parasympathetic (i.e., cardiovagal) function. Initial laboratory evaluation for autonomic neuropathies includes fasting glucose or oral glucose tolerance test, thyroid function tests, kidney function tests, vitamin-B12, serum, and urine protein electrophoresis with immunofixation. Other laboratory tests should be guided by the clinical context. Reduced intraepidermal nerve density on skin biopsy is a finding, not a diagnosis. Skin biopsy can be helpful in selected individuals for the diagnosis of disorders affecting small nerve fibers; however, we strongly discourage the use of skin biopsy without clinical–physiological correlation. Ambulatory blood pressure monitoring may lead to early identification of patients with cardiovascular autonomic neuropathy in the primary care setting. Disease-modifying therapies should be used when available in combination with nonpharmacological management and symptomatic pharmacologic therapies. Autonomic function testing can guide the therapeutic decisions and document improvement with treatment.

Summary A systematic approach guided by the autonomic history and standardized autonomic function testing may help clinicians when identifying and/or counseling patients with autonomic neuropathies. Treatment should be individualized and disease-modifying therapies should be used when available.

Keywords Autonomic neuropathies · Skin biopsy · Autonomic reflex screen · Amyloidosis · COVID-19

Introduction

Autonomic neuropathies are a group of disorders characterized by damage to small unmyelinated or thinly myelinated autonomic nerves that are responsible for the regulation of involuntary physiologic processes including, but not limited to, heart rate, blood pressure, respiration, digestion, and sexual function [1]. Peripheral autonomic neuropathies may result from diverse causes, such as inherited disorders, metabolic derangements, exposure to toxins or drugs, autoimmune or inflammatory diseases, or paraneoplastic disorders (Table 1). Autonomic neuropathies may occur in conjunction with somatic neuropathies, which can affect large sensory and/or motor fibers and/or small sensory fibers. Detailed characterization of the somatic nerve disorder (e.g., demyelinating vs. axonal injury) is helpful for diagnostic purposes. Autonomic neuropathies may also occur in isolation. Diabetes or metabolic syndrome are the most common causes of autonomic neuropathies. The prevalence of autonomic involvement in diabetes increases with the duration of the disease, but autonomic dysfunction can be an early manifestation of the disease or caused by treatments (Table 1) [2]. Some patients with objective evidence of impairment of
| Etiology                  | Clinical presentation                                                                                                                                                                                                 | Testing*                                                                 | Treatment                                                                                           |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Immune-mediated          | |                                                                                                                                                                                                                  | |                                                                                                      |
| AAG                      | Acute; nOH; GI hypomotility; hypotonic bladder; anhidrosis; mydriasis; genitourinary symptoms                                                                                                                       | Labs: + α-3 nAch abs (50%); pupillometry, GI motility, and urodynamic studies can be helpful | Immunotherapy 12w treatment trial of IVIG 0.4 g/kg/w or 1 g IVMP/w; consider long-term immunosuppressant if response to trial (azathioprine, mycophenolate, or rituximab) |
| Acute cholinergic neuropathy | Acute; sicca syndrome; hypotonic bladder; GI hypomotility; erectile failure; mydriasis                                                                                                                                | Labs: + α-3 nAch abs; pupillometry, GI motility, and urodynamic studies can be helpful | Immunotherapy – Limited data. Similar to AAG                                                                 |
| Acute sympathetic neuropathy | Acute; previous viral infection; nOH; ejaculatory dysfunction; sphincter dysfunction; Horner; anhidrosis, nOH                                                                                                      | Labs: + α-3 nAch abs                                                                                     | Immunotherapy – Limited data. Similar to AAG                                                                 |
| Acute immune GI dysmotility | Acute/subacute (< 6 months); previous viral infection; GI hypomotility; intestinal pseudo-obstruction; achalasia; gastroparesis/slow intestinal transit; pyloric stenosis; rarely anal spasm | Labs: α-3 nAch abs negative; + / − neuronal voltage-gated calcium and potassium channel antibodies; GI motility studies are abnormal | Immunotherapy – Limited data. Similar to AAG                                                                 |
| Guillain-Barré syndrome | Acute (< 4 weeks); viral infection; somatic (motor and/or sensory) involvement is frequent; pure dysautonomia possible; afferent autonomic involvement with tachycardia, labile hypertension, bradycardia, dysrythmia, GI dysmotility, and urine retention | CSF: lymphocytic pleocytosis; EMG/NCS: demyelinating neuropathy vs. axonal neuropathy                   | Immunotherapy IVG 0.4 g/kg/5d or PLEX                                                                 |
| Paraneoplastic           | |                                                                                                                                                                                                                  | |                                                                                                      |
| Panautonomic             | Subacute; generalized autonomic failure; limbic encephalitis (ANNA-1, LGI1/CASPR2, PCA-2); brainstem encephalitis (PCA-2); gait disorders (AP3B2); cognitive disorders, chorea, ataxia (CRMP-5); encephalopathy, myeloneuropathy (NIF); stiff-person syndrome/rigidity (Gly-R); psychosis, seizure, dyskinesia (NMDA) | Labs: Ach-R, ANNA-1, AP3B2, NIF, PCA-2, voltage-gated potassium channel (LGI1/CASPR2), CRMP-5, Gly-R, NMDA antibodies; CT scan CAP and PET-CT to look for malignancy | Treatment of underlying tumor; immunotherapy (limited data – IVIG, IVMP, PLEX)                        |
| Enteric                  | Subacute; GI hypomotility; gastroparesis; associated features with meningencephalomyelitis (GFAP), encephalopathies, gait disorders, etc                                                                                | Labs: Ach-R, ANNA-1, AP3B2, GFAP, NIF, CRMP-5, DPPX (DPP6), LGI1/CASPR2; CT scan CAP; PET-CT to look for malignancy | Treatment of underlying tumor; immunotherapy (limited data – IVIG, IVMP, PLEX)                        |
| LEMS                     | Acute/subacute; muscle weakness with oculobulbar weakness; dry mouth; constipation; erectile dysfunction; anhidrosis; nOH                                                                                           | Labs: + P/Q voltage-gated calcium channel antibodies; EMG/NCS with repeat stimulation = increment; CT scan CAP to look for malignancy | Treatment of underlying tumor; 3,4- DAP; immunotherapy                                                                 |
| Associated with immune disorders | |                                                                                                                                                                                                                  | |                                                                                                      |
| Sjögren’s syndrome       | Subacute/chronic; sicca syndrome; autonomic manifestations vary from OI to nOH, tachycardia; sensory neuronopathy with ataxia                                                                                       | Lip biopsy; Schirmer test; anti-Ro (SSA) /anti-La (SSB) antibodies; ANA; ENA; RF; saliva flow rate; EMG/NCS (sensory neuronopathy, length-independent pattern); rheumatology evaluation | Treatment of Sjögren syndrome (multidisciplinary approach with rheumatology)                                                                             |
| Etiology                          | Clinical presentation                                                                 | Testing*                                                                 | Treatment                                      |
|----------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------|
| Systemic Lupus Erythematous and MCTD | Subacute/chronic; rash; alopecia; arthritis; neuropsychiatric manifestations; autonomic manifestations vary from OI to autonomic failure | ANA; ENA; RF; APLS; Complement (C3,C4,CH50); CBC (hemolytic anemia), lymphopenia, thrombocytopenia; rheumatology evaluation | Immunotherapy for SLE or MCTD                |
| Celiac disease                   | Subacute; GI symptoms with diarrhea; bloating; constipation; gluten intolerance; skin changes; migraine; cerebellar ataxia | Celiac antibodies screening with intestinal biopsy; CBC; LFTs; ANA; ENA; RF | Gluten free diet                              |
| Rheumatoid arthritis             | Subacute/chronic; polyarthritis; variable autonomic involvement                         | Anti-cyclic citrullinated peptide antibodies; ANA; ENA; RF; rheumatology evaluation | Immunotherapy for RA                          |
| Metabolic/nutritional            |                                                                                       |                                                                          |                                               |
| Diabetes                         | Chronic; history of diabetes; distal painful small and/or large fiber neuropathy; retinopathy; neuropathy; foot ulcer; cardiac disease; variable autonomic involvement (tachycardia; OI; AF) | Every pattern can be seen on autonomic testing; Fasting glucose, 2-h glucose tolerance, HbA1c; EMG/NCS; cardiology, nephrology, and ophthalmology evaluation | Treatment of diabetes                         |
| TIND                             | Acute; following rapid glycemic control (insulin, oral hypoglycemic agent, diet); concomitant diabetic retinopathy; ↓ A1c > 1%/month; orthostatic intolerance, nOH, bloating, sweat changes, and sexual dysfunction | A1c with rapid decline; EMG/NCS; ophthalmology evaluation               | Treatment is supportive with the goal of stable glucose control |
| Chronic kidney disease           | Chronic; history of chronic kidney disease +/- dialysis; erectile dysfunction; GI hypomotility; hypo/anhidrosis; hypotension during dialysis; OI; OH; silent myocardial infarction | Kidney function tests; nephrology evaluation                             | Treatment is supportive with treatment of underlying kidney disease |
| Ethyl alcohol                    | Chronic; history of chronic alcohol abuse; erectile dysfunction is most frequent; GI with dyspepsia, constipation, diarrhea; cardiovascular involvement with OI and OH is possible | Liver function test; CBC (macrocytosis); EMG/NCS to look for length-dependent axonal polyneuropathy | Treatment is supportive with abstinence from alcohol and vitamin supplementation (thiamin) |
| Infectious                       |                                                                                       |                                                                          |                                               |
| HIV                              | Acute/subacute/chronic; history of HIV; opportunistic infections; associated with distal symmetric polyneuropathy; dry eyes or dry mouth; constipation; erectile dysfunction; OI; rare OH | HIV testing; EMG/NCS                                                    | Antiretroviral therapy                         |
| Leprosy                          | Subacute/chronic; history of leprosy; discolored patches of skin; painless ulcer; decrease sensitivity to pain and temperature; focal anhidrosis; blunted tachycardia; rare nOH; erectile dysfunction, cardiac autonomic neuropathy | Biopsy lesion/nerve; EMG/NCS with mononeuropathy                         | Rifampicin, dapsone, clofazimine               |
| Chagas disease                   | Subacute/chronic; Palpitation, syncope, and risk for sudden death; mild dysmotility to severe megasophagus and megacolon; OH; cardiac conduction system and myocardial damage | Trypanosoma cruzi antigens/ lysate-based enzyme-linked immunosorbent assay; echocardiogram; EKG; Holter-EKG | Benznidazole, Nifurtimox                      |
| Etiology          | Clinical presentation                                                                 | Testing*                                                                 | Treatment                        |
|-------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------|
| Botulism          | Acute; muscle weakness; cholineric failure; dysphagia; mydriasis; urinary retention; dry mouth; respiratory distress | Neurotoxin in the serum, stool, or contaminated food or by culturing Clostridium botulinum from the stool. EMG/NCS: low CMAPs on NCS. High frequency RNS shows increment | Antitoxin and supportive care    |
| Toxic             |                                                                                       |                                                                          |                                   |
| Heavy metals      | Chronic; history of exposure to heavy metals (thallium, arsenic, mercury); usually with sensorimotor symptoms | Heavy metal screening; EMG/NCS                                           | No specific treatment; symptomatic management |
| Chemotherapy      | Subacute; history of exposure to chemotherapy with neurotoxic properties (e.g., cisplatinum, vincristine, paclitaxel, taxol, doxorubicin, cytosine arabinoside, PD-1 inhibitors); usually with sensorimotor symptoms | EMG/NCS                                                                  | Discontinue offending agent      |
| Systemic disorder |                                                                                       |                                                                          |                                   |
| Light chain amyloidosis | Subacute/chronic; 20% with neuropathy; wide spectrum of symptoms: cardiovascular, GI, genitourinary; weight loss and fatigue (50%); periorbital/facial purpura; hepatomegaly; macroglossia; small fiber neuropathy usually associated with large fiber neuropathy; 75% of patients with AF and painful length-dependent sensory-motor neuropathy; 25% with pure autonomic failure or with somatic neuropathy without autonomic symptoms | Immunofixation of serum and urine with free light chain assay; fat aspirate; bone marrow/skin/minor salivary gland nerve biopsy for Congo red staining; mass spectroscopy; echocardiogram with strain assessment; troponin T and N-terminal pro BNP; EMG/NCS; EKG | Stem cell transplantation; chemotherapy; daratumumab (CD-38 directed monoclonal antibody) |
| Porphyria         | Acute/paroxysmal; severe and diffuse abdominal pain; constipation; nausea; confusion; psychiatric disturbances; autonomic instability (tachycardia, hypertension) | Urinary and stool porphyrins, %-aminolevulinic synthetase level          | alkaline heme, small interfering RNA (givosiran) |
| Hereditary        |                                                                                       |                                                                          |                                   |
| TTR amyloidosis   | Chronic; length-dependent small fiber sensorimotor polyneuropathy with loss of pain and temperature; heart failure; arrhythmia; nephrotic disease; bilateral carpal tunnel syndrome; autonomic involvement is variable with possible AF, erectile dysfunction, constipation, genitourinary abnormalities | TTR gene analysis; numerous variants, most common = Val30Met in Portugal, Brazil, Sweden, and Japan; Val122Ile mutations = most common in African American; EMG/NCS; EKG | Suppression of TTR synthesis (interfering RNA = Patisiran, antisense oligonucleotide = Inotersen); TTR stabilization (Tafamidis); liver transplantation |
| Fabry disease     | X-linked; acroparesthesia; fatigue; hearing loss; corneal opacity; renal dysfunction; skin (angiokeratomas); modest autonomic dysfunction with hypohidrosis; impotence; gastrointestinal dysfunction | α-galactosidase enzyme activity in the blood                              | Enzyme replacement therapy       |
| HSAN              | Chronic; variable phenotypes—juvenile to adult presentation; profound distal sensory loss, acral mutilation; absence of tears and recurrent pneumonias (HSAN-III); ulcers; variable autonomic and motor disturbances; involvement of afferent limb of baroreflex with hypertensive crisis (HSAN-III) | Genetic testing: ELP1/IKBAP, SPTLC1, HSN2, NTRK1; cold pressor test and measure of vasopressin characteristic of afferent baroreflex failure in some patients | No specific treatment; carbidopa helpful to prevent excessive blood pressure variability |
| Etiology       | Clinical presentation                                                                     | Testing*                                                                 | Treatment                                                                                       |
|---------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| CANVAS        | Cerebellar ataxia, neuropathy, vestibular areflexia; cold feet, erectile dysfunction, postural lightheadedness, constipation dry mouth or eyes. | Genetic testing: AAGGG repeat expansion in the second intron of replication factor C subunit 1 (RFC1) gene | No specific treatment                                                                           |
| Unknown etiology |                                                                                         | TST with segmental anhidrosis +/- compensatory hyperhidrosis, hyporeflexia, tonic pupils | No specific treatment. Prevention of heat stroke (cooling vest, misting fans, hydration)         |
| Ross syndrome | Chronic; Ross triad = segmental anhidrosis +/- compensatory hyperhidrosis, hyporeflexia, tonic pupils | TST with segmental anhidrosis +/- hyperhidrosis. QSART and TST with postganglionic pattern of sudomotor involvement. ARS with mild cardiovagal and adrenergic impairment (25% of patients); ophthalmology evaluation with dilute pilocarpine test | No specific treatment. Possible evolution to Ross syndrome                                       |
| Holmes Adie   | Chronic; hyporeflexia, tonic pupils                                                        | Ophthalmology evaluation; dilute pilocarpine test                           | No specific treatment. Possible evolution to Ross syndrome                                       |

*Autonomic reflex testing and thermoregulatory sweat test (if available) are helpful in establishing the diagnosis of peripheral autonomic neuropathy. Autonomic reflex screen should be performed expeditiously in all cases of suspected autonomic neuropathy to characterize the pattern of autonomic involvement and permit prompt and appropriate treatment.*

α-3 nAch abs, alpha-3 nicotinic acetylcholine ganglionic antibodies; AAG, autoimmune autonomic ganglionopathy; Ach-R, acetylcholine receptor α-1 subunit; AF, autonomic failure; ANA, anti-nuclear antibodies; ANNA-1, Antineuronal nuclear antibody 1; AP3B2, adaptor protein 3B2; APLS, antiphospholipid syndrome; ARS, autonomic reflex screen; CANVAS, cerebellar ataxia, neuropathy, and vestibular areflexia syndrome; CASPR2, contactin-associated protein-2; CBC, complete blood count; CMAP, compound muscle action potential; CRMP-5, collapsin response-mediator protein-5; CT CAP, computed tomography scanner of the chest-abdomen-pelvis; DPPX, dipeptidyl peptidase-like 6; EKG, electrocardiogram; EMG/NCS, electromyogram/nerve conduction study; ENA, extractable nuclear antigen antibodies; GFAP, glial fibrillary acidic protein; GI, gastrointestinal; Gly-R, glycine receptor; HSAN, hereditary sensory and autonomic neuropathy; IVIG, intravenous immunoglobin; IVMP, intravenous methylprednisolone; LEMS, Lambert-Eaton myasthenic syndrome; LFTs, liver function tests; MCTD, mixed connective tissue disorder; NIF, neuronal intermediate filament; MDMA, n-methyl-o-aspartate; nOH, neurogenic orthostatic hypotension; OI, orthostatic intolerance; PCA-2, Purkinje cell cytoplasmic antibodies 2; PET, positron emission tomography; PLEX, plasmapheresis; QSART, quantitative sudomotor axon reflex test; RF, rheumatoid factor; RNA, ribonucleic acid; SLE, systemic lupus erythematosus; TIND, treatment induced neuropathy of diabetes; TST, thermoregulatory sweat test; TTR, transthyretin
autonomic nerves on testing do not have an identifiable etiology, even after extensive workup.

Knowledge of the anatomic, neurochemical, and functional organization of the autonomic nervous system is critical for the diagnosis and treatment of autonomic neuropathies. The peripheral autonomic nervous system can be divided into the sympathetic, parasympathetic, and enteric divisions. Impairment of cholinergic postganglionic sympathetic fibers is frequent in autonomic neuropathies and these pathologic findings account for the loss of sweating, but compensatory hyperhidrosis can be seen. The impairment of heart rate control (heart rate variability) is predominately due to parasympathetic denervation and can be an early manifestation of autonomic neuropathy, especially in the setting of diabetes and amyloidosis. Neurogenic orthostatic hypotension is caused by damage or loss of small autonomic fibers in afferent and efferent nerves of the baroreflex arcs, with impairment of sympathetic noradrenergic reflex vasoconstriction. When the splanchnic vascular bed is extensively denervated, orthostatic hypotension can also be marked. Disturbance of bladder function, erectile dysfunction, and pupillary abnormalities may also be the manifestations of peripheral nerve disease when autonomic fibers to these structures are involved.

There have been recent reviews focusing on the clinical approach to patients with suspected autonomic neuropathies [3•, 4•]. The key part of the evaluation is a comprehensive autonomic history to define the temporal course of the symptoms and identify associated illnesses. The clinical evaluation and testing are guided by the history (Fig. 1) [5].

Here, we review evidence-based recommendations for the diagnosis of autonomic neuropathies focusing on non-invasive laboratory evaluation of autonomic function, advances in the field of autoimmune and genetic autonomic disorders, and the role of tissue biopsy in the clinical setting. We also discuss the role of other non-invasive tests of autonomic function and the possible association between the coronavirus disease 2019 (COVID-19) and autonomic neuropathy. Finally, we review recent advances and future directions for the treatment of peripheral autonomic neuropathies focusing on disease-modifying therapies (when available) and symptomatic pharmacologic therapies.

**Diagnosis of Autonomic Neuropathies: Evidence-Based Recommendations, Recent Advances, and Future Directions**

**Electrodiagnostic Assessment of the ANS—Autonomic Reflex Screen and Thermoregulatory Sweat Test**

The goals of autonomic testing are to recognize the presence, distribution, and severity of autonomic dysfunction. In some cases, testing can detect patterns of autonomic impairment related to specific disorders. The American Autonomic Society, the International Society for Autonomic Neuroscience, the European Federation of Autonomic Societies, and the American Academy of Neurology have developed and endorsed consensus guidelines for clinical autonomic testing [6••]. The autonomic reflex screen is a validated approach to assess sympathetic postganglionic sudomotor, cardiovascular sympathetic noradrenergic, and cardiac parasympathetic (i.e., cardiovagal) function (Fig. 2) [6••]. Results should be compared to normative values for age and sex. The composite autonomic severity score (CASS), a validated instrument that...
quantifies the severity and distribution of autonomic failure, can be derived from the autonomic reflex screen [6••]. Quantitative sudomotor axon reflex testing (QSART) assesses postganglionic sympathetic sudomotor function [7]. Cardiovagal function is assessed with heart rate responses to deep breathing (the most widely used method currently in clinical practice compared to the expiratory-inspiratory (E:I) ratio), the Valsalva ratio, and the vagal baroreflex sensitivity (slope of the relationship between RR interval and blood pressure in early phase II of the Valsalva maneuver) [8, 9]. Cardiovascular noradrenergic function is evaluated by assessing blood pressure responses to Valsalva maneuver and passive head-up tilt [8]. Quantitative indices of cardiovascular noradrenergic function, i.e., blood pressure recovery time or adrenergic baroreflex sensitivity, may be used [10]. Classic orthostatic hypotension is indicated by a sustained drop > 20 mmHg in systolic blood pressure and/or > 10 mmHg in diastolic blood pressure within 3 min during tilt table test. In delayed orthostatic hypotension, the drop in blood pressure becomes apparent after a prolonged standing posture (> 3 min). A neurogenic etiology of orthostatic hypotension is indicated by a lack of reflex vasoconstriction during the Valsalva maneuver [6••]. An insufficient compensatory increase in heart rate in relation to orthostatic hypotension is also a marker of neurogenic orthostatic hypotension [11••]. In a prospective study of 402 patients with orthostatic hypotension, a neurogenic etiology was reliably identified when the ratio of orthostatic heart rate changes over systolic blood pressure changes at 3 min of tilt was < 0.5 beats/min per mmHg [11••]. Importantly, similar findings were reported with active standing [12].

The integrity of central and peripheral sympathetic sudomotor pathways can be assessed by the thermoregulatory sweat test [13]. This test is performed in a temperature and humidity-controlled room and the body is warmed up to a core temperature of 38 °C. The patient lies supine with exposed body surface covered with an indicator powder that changes color when wet. Digital photographs with pixel counter quantify the percentage of anhidrosis [13].

Standardized autonomic function testing plays a role in accurate diagnosis of most autonomic neuropathies but also monitoring of treatment efficacy as demonstrated in autoimmune autonomic ganglionopathies [14••]. Although standardized autonomic function testing provides an accurate measure of autonomic function, one of the main limitations of electrodiagnostic assessment of the autonomic nervous system is the limited availability of dedicated autonomic laboratories and specialty trained clinicians.

**Electrodiagnostic Assessment of the ANS—Other Tests of Autonomic Function**

Additional autonomic tests may be used in select research settings but at this time are not practical for

---

Fig. 2 Illustrative example: autonomic reflex screen of a patient with diabetic autonomic neuropathy
routine clinical use in patients with autonomic neuropathies. These tests include the study of sympathetic skin response, heart rate variability, corneal confocal microscopy, microneurography, electrical-evoked potentials, and laser-evoked potentials. The cold pressor test and analysis of the blood pressure response to sustained handgrip may have a role in patients with suspected involvement of the afferent limb of the baroreflex (e.g., afferent baroreflex failure) [15]. Quantitative sensory testing is a psychophysical assessment of different somatosensory thresholds and may be helpful in the evaluation of patients with small fiber neuropathy who often have both sensory and autonomic complaints; however, the results are highly dependent on methodology and the full cooperation of the subject [16].

### Laboratory Tests

Initial laboratory evaluation for autonomic neuropathies includes complete blood count, basic metabolic panel, thyroid function tests, fasting glucose or oral glucose tolerance test, vitamin-B12, and serum and urine protein electrophoresis [4•]. Secondary causes of autonomic dysfunction should be ruled out and testing may include screening for adrenal insufficiency and pheochromocytoma. Other tests should be guided by clinical suspicion (e.g., IgA tissue transglutaminase antibodies if there is a suspicion of celiac disease).

Measurement of plasma catecholamines may be helpful in a few selected cases. For example, plasma nor-epinephrine is often elevated in patients with afferent baroreflex failure [17••].

Laboratory testing plays an important role in identifying autoimmune etiologies of autonomic neuropathy. If there is a clinical suspicion of autoimmuneopathy, testing often includes antinuclear antibodies (ANA), extractable nuclear antigen antibodies (including SS-A/SS-B antibodies), C-reactive protein, and erythrocyte sedimentation rate. Some paraneoplastic nuclear antibodies are highly associated with autonomic neuropathies, especially the Type 1 Antineuronal Nuclear Autoantibody (ANNA-1 or anti-Hu) and Collapsing Response-Mediator Protein 5 antibody (CRMP-5 or Anti-CV2) [18]. The α3 nicotinic acetylcholine ganglionic antibodies are membrane receptor antibodies that are classically associated with autoimmune autonomic ganglionopathy. One should always interpret the presence of this antibody in light of the clinical presentation because they have also been reported in individuals without objective evidence of autonomic impairment. A level > 0.40 nmol/L had high specificity and moderate sensitivity for severe autonomic failure, whereas levels of less than 0.20 nmol/L may not be clinically relevant [19]. Karagiorgou and colleagues recently demonstrated that a cell-based assay for α3 nicotinic acetylcholine ganglionic antibodies is more specific for the diagnosis of autoimmune autonomic ganglionopathy compared to the commercially available radioimmunoassay precipitation assay [20•]. Further studies are necessary to investigate the clinical significance of trisulfated disaccharide IdoA2S-GlcNS-6S antibodies (TS-HDS), fibroblast growth factor receptor 3 (FGFR3), and muscarinic (M3) acetylcholine receptor antibodies in patients with autonomic neuropathies. Preliminary findings do not suggest a benefit from treatment with immune globulin in individuals with small fiber neuropathy with TS-HDS and FGFR3 autoantibodies [21].

Advances in genetic studies have led to the identification of new autonomic neuropathies and newly approved gene-modifying therapies. Hereditary transthyretin variant amyloidosis (ATTRv) is the most common form of hereditary amyloidosis. More than 130 mutations have been identified to date, and some mutations predominately cause plyoneuropathy, whilst other mutations cause cardiomyopathy or mixed phenotypes [22]. Val-30Met is the most common ATTRv mutation worldwide but the clinical presentation is variable among individuals with the mutation. Early suspicion and recognition of ATTRv amyloidosis can lead to an earlier diagnosis and treatment. If there is clinical suspicion of amyloid neuropathy, DNA sequencing of the transthyretin gene can support or exclude a diagnosis of ATTRv amyloidosis [23•]. Furthermore, genetic testing is helpful in healthy but potentially at-risk persons with a family history of ATTRv amyloidosis. However, the penetrance of ATTRv is incomplete in carriers. Therefore, the detection of amyloid deposits on biopsy samples is crucial to confirm the diagnosis [24••]. The sensitivity of biopsy in different sites varies but the specificity is high for a diagnosis of ATTRv amyloidosis [25]. Echocardiogram and cardiac magnetic resonance imaging are important investigations for detecting cardiac amyloidosis. In cases with hypertrophic cardiopathy with negative biopsy findings, radionuclide bone scintigraphy with technetium-labeled bisphosphonates can localize cardiac amyloid deposits and may obviate the need for endomyocardial biopsy [26]. Characterizing the subtype of amyloid protein by mass spectrometry or immunohistochemistry can enhance diagnostic accuracy and guide management [27, 28].

Autonomic dysfunction has been recently recognized in cerebellar ataxia, neuropathy, and vestibular areflexia—“CANVAS”—syndrome [29]. CANVAS is due to AAGGG repeat expansion in the second intron of replication factor C subunit 1 (RFC1) gene. In a case series of 23 patients, 83% had evidence of autonomic dysfunction; all patients had at least one autonomic symptom and 91% had more than two symptoms. Cold feet (78%), erectile dysfunction (78% of men), light-headedness (65%),

[Springer]
constipation (65%), and sicca syndrome (52%) were the most common symptoms reported. Thirty percent of patients fulfilled the criteria for orthostatic hypotension. Autonomic dysfunction in CANVAS may be related to a primary ganglionopathy involving the autonomic, facial, trigeminal, vestibular, and sensory ganglia and their projections. Another study demonstrated that biallelic repeat expansions in RFC1 were a frequent cause of whole-exome sequencing negative hereditary sensory and autonomic neuropathy with chronic cough and ataxia [30]. Genetic testing with repeat-primed polymerase chain reaction to detect intronic expansions should be performed in cases with suspicion of CANVAS syndrome.

Skin Biopsy

Antibodies against the cytoplasmic protein gene product 9.5 (PGP9.5) can visualize the rich cutaneous innervation via bright-field immunohistochemistry. Evidence of reduced or absent intraepidermal nerve fibers on punch skin biopsy, a minimally invasive technique, may be used to support a diagnosis of small fiber neuropathy. The sensitivity and specificity of skin biopsy in the diagnosis of small fiber neuropathy vary between 78–92% and 65–90% respectively [31]. A diagnosis of small fiber neuropathy is made when nerve fiber density is in the lowest 5th percentile compared to normative values for both age and gender in the appropriate clinical context [32]. Punch skin biopsy is billable to insurance companies and many commercial laboratories are claiming to provide the same service and diagnostic accuracy as research laboratories. This has led to an increase in testing and diagnosis, often without clinical–physiological–pathological correlation.

Several points are worth discussing. First, reduced intraepidermal nerve density is a finding, not a diagnosis. Skin biopsy alone should not be used to diagnose small fiber neuropathy. PGP9.5 staining does not provide any information about small nerve fiber functions. This may explain the lack of correlation between intraepidermal nerve fiber density and neuropathic pain [33]. The use of other molecular markers linked to different subtypes of skin nerve fibers might provide a better clinical–physiological–pathological correlation [34]. Second, objective morphometric assessment of small nerve fibers should be performed in a body region where there are symptoms and clinicians should always correlate the biopsy findings with the clinical context taking into consideration that functional changes are not always associated with the loss of nerve fibers. For example, conditions associated with neuropathic pain secondary to some channelopathies are not always associated with a reduction in intraepidermal nerve fiber density [35]. Finally, the analysis of skin biopsy results should follow a rigorous process: (1) results of intraepidermal nerve fiber density should be interpreted based on the site where the biopsy is taken because control data exist only for a few body sites; (2) the results should be compared with a control population using published data; and (3) the report should mention standard deviations or interquartile intervals, and percentage of truly abnormal by a predefined outcome measure.

Skin biopsies may also be helpful to identify pathological hallmarks in different diseases. For example, visualization of amyloid deposition confirmed by Congo red stain in the subcutaneous tissue is sensitive and specific for diagnosing systemic amyloidosis [36]. Skin biopsy also has great potential for the diagnosis of synucleinopathies [37]. However, alpha-synuclein deposit in cutaneous autonomic nerve fibers has also been found in individuals with postural tachycardia with neuropathic features or long-COVID [38•, 39•]. Further studies are needed to confirm whether alpha-synuclein deposition in these individuals reflects a reactive process or an early stage of more widespread synucleinopathies.

Ambulatory Blood Pressure Monitoring—an Underutilized Tool in Autonomic Neuropathies?

Ambulatory blood pressure monitoring (ABPM) provides some advantages over the measurement of orthostatic vital signs in the autonomic laboratory or during office visits. It allows for “real-life” assessment while patients perform daily activities; it determines diurnal and nocturnal blood pressure patterns that are characteristics of autonomic failure such as supine hypertension, labile blood pressure, non-dipping of nocturnal blood pressure; it also allows for the evaluation of the impact of antihypertensive and pressor medications [40]. One study reported that daytime blood pressure variability was a good screening tool to identify patients with autonomic failure from controls; however, correlation analysis between quantitative assessment of autonomic function and ambulatory blood pressure was not performed [41]. There is a need to standardize parameters derived from ABPM. High variability of blood pressure with low heart rate variability over a 24 h may allow for accurate identification of patients with autonomic neuropathy with autonomic failure. This approach may lead to early identification of patients with autonomic neuropathy in the primary care setting, earlier referral to specialized autonomic evaluation if necessary, reduce delay in treatment, and decrease unnecessary testing.
COVID-19 and Autonomic Neuropathy—What Is the Evidence?

The novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection has been associated with para-infectious neurological and autonomic abnormalities [42••]. There is concern that post-acute sequelae of COVID-19 (also called “long-haul COVID” “long-COVID” or “post-COVID syndrome”) include abnormalities of autonomic cardiovascular function, which may be associated with various symptoms such as fatigue, “brain fog,” sensory changes, and orthostatic intolerance [43]. The pathophysiological mechanisms of post-acute cardiovascular autonomic dysfunction in COVID-19 are not well understood. Proposed mechanisms include dysfunction of the extended autonomic nervous system, immune dysregulation triggered by the infection, dysfunction of the renin–angiotensin–aldosterone system, or a restricted autonomic neuropathy causing impaired vasomotor and venomotor tone in the lower limbs among others [44]. Cases of autonomic dysfunction beyond postural tachycardia syndrome have been reported, including phenomena such as small fiber neuropathy [45], neurocardiogenic syncope, and post-COVID-19 exacerbation of paroxysmal hypothermia and hyperhidrosis [46]. Post-COVID-19 acute inflammatory demyelinating polyneuropathy has been described as well [47]. In our experience, however, most individuals with long-COVID who present to the autonomic clinic do not have objective evidence of autonomic neuropathy. In a retrospective series of 27 patients with a confirmed history of COVID-19 infection referred for autonomic testing for symptoms concerning for para-/postinfectious autonomic dysfunction, autonomic symptoms developed between 0 and 122 days following the acute infection and included lightheadedness (93%), orthostatic headache (22%), syncope (11%), hyperhidrosis (11%), and burning pain (11%). Twenty-two percent of patients fulfilled the criteria for postural tachycardia syndrome, and 11% had borderline findings to support orthostatic intolerance. The most common autonomic testing finding was orthostatic intolerance, often without objective hemodynamic abnormalities on testing [48••]. In a study of 16 young adults who tested positive for SARS-CoV-2, resting heart rate and blood pressure were not different compared to controls (N = 14); however, muscle sympathetic nerve activity was higher in COVID subjects compared to controls during head-up tilt with a group-by-position interaction in muscle sympathetic nerve activity burst incidence, as well as heart rate, in response to tilt. The results of this study suggest that These results indicate resting sympathetic activity may be elevated following SARS-CoV-2 infection [49]. Further studies are necessary to investigate the association between autonomic neuropathy and COVID-19.

Treatment of Autonomic Neuropathies

The treatment of autonomic neuropathies is based on the combination of disease-modifying therapies (when available), nonpharmacological management, and symptomatic pharmacologic therapies. The autonomic reflex screen is helpful to identify initial deficits and guide treatment [14••].

Disease-Modifying Therapies—Focus on Hereditary Transthyretin Amyloidosis

Liver transplantation replaces the primary source of mutant transthyretin. Liver transplantation is associated with improved long-term survival in hereditary transthyretin amyloidosis. Nevertheless, peripheral neuropathy and cardiomyopathy may progress following liver transplantation and genotype influences post-transplantation survival [50]. Furthermore, adverse effects of surgery and complications of long-term immunosuppression are limitations of this approach. Novel treatments for hereditary transthyretin amyloidosis (hATTR) are now available. Tafamidis meglumine, a kinetic TTR stabilizer, can be administered orally and prevents misfolding and deposition of mutated TTR [51]. Two studies have demonstrated some benefit of tafamidis in early-stage hATTR polyneuropathy compared to placebo [52, 53]. Outcomes were mixed in patients with mid-and late-stage hATTR and worsening of baseline autonomic function and cardiac disease has been reported [54]. Diflunisal, a nonsteroidal anti-inflammatory drug, has TTR-stabilizing properties; however, adverse events such as renal failure or thrombocytopenia may limit its use. Oligonucleotide-based gene therapies (patisiran and inotersen) have been recently approved by the Food and Drug Administration in the United States for the treatment of hATTR. These agents have demonstrated efficacy in patients with early-and late-stage disease and improve, halt, or slow neuropathy progression.

Symptomatic Pharmacologic Therapies—Focus on Cardiovascular Manifestations of Autonomic Neuropathies

Neurogenic Orthostatic Hypotension

Orthostatic hypotension is associated with a risk of falls, cognitive impairment, and dementia [55]. The nonpharmacological management of orthostatic hypotension should be individualized (Table 2) [56••]. Available options for the pharmacological management of
neurogenic orthostatic hypotension are limited. Fludrocortisone is a synthetic mineralocorticosteroid that can be helpful in combination with adequate hydration and liberalizing dietary sodium. Side effects of fludrocortisone include supine hypertension and hypokalemia [57]. Droxidopa (a precursor of norepinephrine) and midodrine (an alpha-receptor agonist) are the only drugs approved by the Food and Drug Administration for the treatment of neurogenic orthostatic hypotension [57]. Droxidopa is most beneficial in patients with low supine plasma norepinephrine levels (< 200 pg/mL) [58]. Pyridostigmine, a reversible inhibitor of acetylcholinesterase, increases the availability of acetylcholine to bind to muscarinic or nicotinic receptors. The pressor effect of pyridostigmine may be suboptimal compared to other drugs, but it can be used as an add-on therapy in patients with moderate to severe autonomic failure [59].

Norepinephrine transporter (NET) inhibition is a mechanism that is being studied to increase blood pressure in patients with autonomic failure. Shibao and colleagues first showed that atomoxetine induced a hypertensive response in a small group of patients with central autonomic failure [60–62]. In a recent study, Kaufmann and colleagues reported the safety and efficacy of ampreloxetine to treat neurogenic orthostatic hypotension, in a small phase II clinical trial [63•]. This study demonstrated that Ampreloxetine was safe and improved orthostatic symptoms and seated/standing blood pressure with little change in supine blood pressure [63•]. Unfortunately, a press release from the company announced the failure of the phase III study due to a lack of efficacy [64]. We are awaiting for the results of another phase II trial that is investigating the effect of atomoxetine in the symptomatic management of nOH (ClinicalTrials.gov: NCT02796209).

### Table 2 Symptomatic management of cardiovascular autonomic dysfunction (midodrine, etc.)

| Drug              | Mechanism of action                          | Dosing                                               | Side effects                                                                 |
|-------------------|-----------------------------------------------|------------------------------------------------------|------------------------------------------------------------------------------|
| Orthostatic hypotension |                                               |                                                      |                                                                               |
| Midodrine         | Alpha-1 agonist                               | Tablet: 2.5 mg, 5 mg, 10 mg                          | Scalp pruritus, piloerection, dysuria, paresthesia, supine hypertension       |
|                   |                                               | Dosage: 2.5 to 10 mg, orally, 3–4 times per day       |                                                                               |
| Droxidopa         | Precursor of norepinephrine                   | Tablet: 100 mg, 200 mg, 300 mg                       | Headaches, hypertension, dizziness, nausea                                   |
|                   |                                               | Dosage: 100 to 600 mg, orally, 3 times per day        |                                                                               |
| Fludrocortisone   | Mineralocorticoid. Promotes increased reabsorption of sodium and loss of potassium from renal distal tubules | Tablet: 0.1 mg                                      | Cardiac failure, cardiomegaly, edema, hypertension                           |
|                   |                                               | Dosage: 0.1 to 0.2 mg, orally, daily in the morning   |                                                                               |
| Pyridostigmine    | Acetylcholinesterase inhibitor                | Tablet: 30 mg, 60 mg                                | Diarrhea, abdominal pain, muscle contraction/twitching, increase secretion    |
|                   |                                               | ER: 180 mg                                           |                                                                               |
|                   |                                               | Dosage: 30 to 60 mg 3 times daily, orally, or 180 mg ER daily, orally, in the morning |                                                                               |
| Atomoxetine       | NE transporter inhibitor                      | Dosage: 18 mg daily, orally,                        | Supine hypertension, urinary urgency                                         |
| Octreotide        | Somatostatin analog reducing postprandial splanchic hyperemia induced by gastrointestinal vasodilatory peptides | Dosage: 0.2–1.6 mg/kg qd, subcutaneous               | Injection site discomfort, erythema, gastrointestinal disturbances, flushing, cholelithiasis, hyperglycemia, supine hypertension |
| Supine hypertension |                                               |                                                      |                                                                               |
| Clonidine         | Central alpha-2 agonist                       | 0.1 mg, orally, with dinner                         | Fatigue, hypotension, lethargy, headache, abdominal pain                     |
| Losartan          | Angiotensin II receptor antagonist             | 25 to 50 mg, orally, at bedtime                     | Increase K +, hypotension, cough                                             |
| Nifedipine        | Calcium channel blocker                       | 10–30 mg short-acting, orally, at bedtime, or 30 mg ER | Edema, hypotension, flushing, nausea, dizziness, headache                    |
| Nitroglycerin patch | Vasodilator, nitric oxide donor             | 0.1 mg/h patch at bedtime, remove in the morning    | Headache, hypotension, edema                                                  |
| Sildenafil        | Phosphodiesterase inhibitor, potentiates nitric oxide | 25 mg, orally, at bedtime                         | Flushing, dyspepsia, headache, vision disturbance, epistaxis                 |
| Eplerenone        | Mineralocorticoid receptor antagonist         | 50 mg, orally, at bedtime                           | Hyperkalemia, increased serum creatinine                                     |

Norepinephrine transporter (NET) inhibition is a mechanism that is being studied to increase blood pressure in patients with autonomic failure. Shibao and colleagues first showed that atomoxetine induced a hypertensive response in a small group of patients with central autonomic failure [60–62]. In a recent study, Kaufmann and colleagues reported the safety and efficacy of ampreloxetine to treat neurogenic orthostatic hypotension, in a small phase II clinical trial [63•]. This study demonstrated that Ampreloxetine was safe and improved orthostatic symptoms and seated/standing blood pressure with little change in supine blood pressure [63•]. Unfortunately, a press release from the company announced the failure of the phase III study due to a lack of efficacy [64]. We are awaiting for the results of another phase II trial that is investigating the effect of atomoxetine in the symptomatic management of nOH (ClinicalTrials.gov: NCT02796209).
Most patients with orthostatic hypotension and supine hypertension have normal seated blood pressures. Therefore, it is important to consider the 24-h blood pressure profile and not to use the sitting blood pressure as a target to assess treatment efficacy. Although it is crucial to avoid iatrogenic causes of orthostatic hypotension, there is no clear epidemiological relationship between orthostatic hypotension and the use of antihypertensive medications. A recent meta-analysis of 18,466 individuals from randomized clinical trials for the treatment of essential hypertension has shown that blood pressure-lowering treatment decreased the risk for orthostatic hypotension [65••]. Because individuals with autonomic neuropathy are at increased risk of cardiac arrhythmia and sudden death [66], it is important to avoid the use of medications that affect cardiac repolarization and consequently prolong the QT if possible.

**Supine Hypertension**

Supine hypertension is defined as a systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least 90 mmHg [67]. More than 50% of patients with neurogenic orthostatic hypotension may suffer from supine hypertension [68]. Treatment of supine hypertension can worsen OH and vice versa. Nocturnal pressure natriuresis from supine hypertension also worsens orthostatic hypotension. Supine hypertension is associated with cardiac hypertrophy and kidney failure, which may increase cardiovascular and renal disease, and mortality. Supine hypertension is also linked to impaired cerebral autoregulation [69••]. Short-acting antihypertensives such as angiotensin II receptor blockers (e.g., low dose losartan) and calcium channel blockers (e.g., nifedipine) might be considered (Table 2). On the other hand, alpha-blockers and diuretics can exacerbate orthostatic hypotension and should be avoided. Some patients with supine hypertension retain the normal pattern of blood pressure dipping at night, with elevated blood pressure mostly early in the night. These patients may benefit from ingestion of a carbohydrate-rich snack at bedtime to induce postprandial hypotension [70]. In one study, local heat therapy also effectively lowered overnight blood pressure in patients with autonomic failure and supine hypertension [71•].

**Labile Blood Pressure**

It is recommended not to “chase” the blood pressure in cases with blood pressure lability secondary to afferent baroreflex failure. Central sympatholytic drugs such as clonidine can be helpful [72]. Vasodilators should be used with caution because they can elicit profound hypotension. Patients should be aware that medications that modify the vascular tone or sympathetic activity can have a drastic effect on the blood pressure precipitating hypertensive crisis or hypotension. Peripheral decarboxylase inhibition with carbidopa reduces blood pressure variability in patients with familial dysautonomia who have afferent lesions of the arterial baroreflex [73]. Further studies are necessary to test this approach in individuals with acquired afferent baroreflex failure.

**Tachycardia**

Symptomatic manifestations of cardiac autonomic neuropathy may include resting sinus tachycardia and exercise intolerance. Higher resting heart rate (> 78 bpm) and a rise in heart rate with time are independent risk predictors for all-cause mortality in patients with diabetes [74]. A fixed heart rate that is unresponsive or poorly responsive (i.e., chronotropic incompetence) to exercise indicates almost complete cardiac denervation. After exclusion of other causes of tachycardia (e.g., anemia, medication, cardiac arrhythmia, recreational drugs), the use of β-adrenergic blockers may be indicated.

**Multidisciplinary Care**

A multidisciplinary approach involving different specialties is necessary for optimal management of the diverse clinical manifestations of autonomic neuropathies.

**Conclusion**

A detailed history and neurological examination guide testing in individuals with peripheral autonomic neuropathies. Workup of autonomic neuropathies may include standardized autonomic function testing, laboratory testing, imaging, and tissue biopsy. Treatment should be individualized and disease-modifying therapies should be used when available. Further studies are necessary to investigate the association between autonomic neuropathy and COVID-19.

**Declarations**

**Conflict of Interest** Guillaume Lamotte serves as the managing editor of the journal *Clinical Autonomic Research*. Paola Sandroni declares no competing interests.

**Human and Animal Rights** This article does not contain any studies with human or animal subjects performed by any of the authors.
References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
•• Of major importance

1. Gibbons CH. Basics of autonomic nervous system function. Handb Clin Neurol. 2019;160:407–18.
2. Freeman R. Diabetic autonomic neuropathy. Handb Clin Neurol. 2014;126:63–79.
3. Kaur D, Tiwana H, Stino A, Sandroni P. Autonomic neuropathies. Muscle Nerve. 2021;63(1):10–21. This is an excellent review which categorizes peripheral autonomic neuropathies based on their acute/subacute or chronic onset.
4. • Lamotte G, Sandroni P. A practical approach to peripheral autonomic neuropathies. Curr Opin Neurol. 2021;34(5):638–47. This review focuses on the practical approach of individuals with peripheral autonomic neuropathies with an emphasis on the autonomic history and physical examination.
5. Goldstein DS, Cheshire WP Jr. The autonomic medical history. Clin Auton Res. 2017;27(4):223–33.
6. •• Cheshire WP, Freeman R, Gibbons CH, et al. Electrodiagnostic assessment of the autonomic nervous system: a consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. Clin Neurophysiol. 2021;132(2):666–82. This is the most recent consensus statement on autonomic testing.
7. Low PA, Caskey PE, Tuck RR, Fealey RD, Dyck PJ. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol. 1983;14:573–80.
8. Low PA. Autonomic nervous system function. J Clin Neurophysiol. 1993;10(1):14–27.
9. Pickering TG, Sleight P. Quantitative index of baroreflex activity in normal and hypertensive subjects using Valsalva’s manoeuvre. Br Heart J. 1969;31(3):392.
10. Vogel ER, Sandroni P, Low PA. Blood pressure recovery from Valsalva maneuver in patients with autonomic failure. Neurology. 2005;65:1533–7.
11. •• Norcliffe-Kaufmann L, Kaufmann H, Palma JA, et al. Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative syndromes. Ann Neurol. 2018;83(3):522–31. This important study validated the ratio of orthostatic heart rate changes over systolic blood pressure changes to identify individuals with neurogenic orthostatic hypotension.
12. Balagny P, Wanono R, d’Ortho MP, Vidal-Petiot E. Reply to validation of the new diagnostic tests for neurogenic orthostatic hypotension. Ann Neurol. 2018;84(6):957–8.
13. Fealey RD, Low PA, Thomas JE. Thermoregulatory sweating abnormalities in diabetes mellitus. Mayo Clin Proc. 1989;64(6):617–28.
14. •• Koay S, Vichayanrat E, Brenner F, et al. Multimodal biomarkers quantify recovery in autoimmune autonomic ganglionopathy. Ann Neurol. 2021;89(4):753–68. This study demonstrated the role of quantitative autonomic function testing to monitor the response to treatment in individuals with autoimmune autonomic ganglionopathy.
15. Robertson D, Hollister AS, Biagiioni I. Arterial baroreflex failure in man. Clin Auton Res. 1993;3:212.
16. Potockova V, Mala S, Hoskovcova L, et al. Thermal quantitative sensory testing as a screening tool for cardiac autonomic neuropathy in patients with diabetes mellitus. Brain Behav. 2022;12(3):e2506.
17. •• Lamotte G, Coon EA, Suarez MD, et al. Standardized autonomic testing in patients with probable radiation-induced afferent baroreflex failure. Hypertension. 2022;79(1):50–6. This study described the pattern of autonomic dysfunction on standardized autonomic testing in patients with probable radiation-induced afferent baroreflex failure.
18. Shouman K, Sandroni P. Antibody testing for suspected autoimmune autonomic dysfunction and small fiber neuropathies. J Clin Neurophysiol. 2021;38(4):274–8.
19. Cutsforth-Gregory JK, McKeon A, Coon EA, et al. Ganglionic antibody level as a predictor of severity of autonomic failure. Mayo Clin Proc. 2018;93(10):1440–7.
20. • Karagiorgou K, Dandoulaki M, Mantegazza R, et al. Novel cell-based assay for alpha-3 nicotinic receptor antibodies detects antibodies exclusively in autoimmune autonomic ganglionopathy. Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1162. https://doi.org/10.1212/NX1.0000000000001162. Print 2022 May.
21. Gibbons CH. A double-blind, placebo controlled trial of Gamunex-C in patient with small fiber neuropathy associated with autoantibodies to TS-HDS and FGF3 (P8-13.002). Neurology. 2022;98(18 Supplement).
22. Gertz MA, Maurermann ML, Grogan M, Coelho T. Advances in the treatment of hereditary transthyretin amyloidosis: a review. Brain Behav. 2019;9(9):e01371.
23. • Adams D, Ando Y, Beirao JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polynuropathy. J Neurol. 2021;268(6):2109–22. This review outlines detailed recommendations to improve the diagnosis of ATTR amyloidosis with peripheral neuropathy.
24. •• Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol, Neurosurg Psychiatr 2022. This review highlights the key advances in the diagnostic techniques, current and emerging management strategies, and biomarker development for disease progression in hereditary transthyretin amyloidosis.
25. Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Current opinion in neurology. 2016;29(Suppl 1):S14–26.
26. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12.
27. Klein CJ, Vrana JA, Thes JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol. 2011;68(2):195–9.
28. Rezk T, Gilbertson JA, Mangione PP, et al. The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. J Pathol Clin Res. 2019;5(3):145–53.
29. Wu TY, Taylor JM, Kilfoyle DH, et al. Autonomic dysfunction is a major feature of cerebellar ataxia, neuropathy, vestibular areflexia “CANVAS” syndrome. Brain. 2014;137(Pt 10):2649–56.
30. Beijer D, Dohrn MF, De Winter J, et al. RFC1 repeat expansions: a recurrent cause of sensory and autonomic neuropathy with autoantibodies to TS-HDS and FGF3 (P8-13.002). Neurology. 2022;98(18 Supplement).
31. Hovaguimian A, Gibbons CH. Diagnosis and treatment of polyneuropathy. Curr Opin Neurol. 2021;34(5):638–47.
32. Provitera V, Gibbons CH, Wendelschafer-Crabb G, et al. A multi-center, multinational age- and gender-adjusted normative
dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg. Eur J Neurol. 2016;23(2):333–8.

33. Shun CT, Chang YC, Wu HP, et al. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain. 2004;127(Pt 7):1593–605.

34. Baskozos G, Sandy-Hindmarsh O, Clark AJ, et al. Molecular and cellular correlates of human nerve regeneration: ADCCYAP1/ PACAP enhance nerve outgrowth. Brain. 2020;143(7):2009–26.

35. Bennett DL, Woods CG. Painful and painless channelopathies. The Lancet Neurology. 2014;13(6):587–99.

36. Wu B, Pak DM, Smith KD, Shinohara MM. Utility of abdominal skin punch biopsy for detecting systemic amyloidosis. J Cutan Pathol. 2021;48(11):1342–6.

37. Wang N, Gibbons CH, Lafo J, Freeman R. alpha-Synuclein in cutaneous autonomic nerves. Neurology. 2013;81(18):1604–10.

38. Levine TD, Bellaire B, Gibbons C, Freeman R. Cutaneous alpha-synuclein deposition in postural tachycardia patients. Ann Clin Transl Neurol. 2021;8(4):908–17. In this study, a subgroup of patients with postural tachycardia had evidence of cutaneous alpha-synuclein deposition.

39. Miglis MG, Seliger J, Shaik R, Gibbons CH. A case series of cutaneous phosphorylated α-synuclein in Long-COVID POTS. Clin Auton Res: Off J Clin Auton Res Soc. 2022;32(3):209–12. In this research letter, the authors report phosphorylated alpha-synuclein in skin biopsy samples in five young patients with long-COVID postural tachycardia syndrome.

40. Guidelines for the clinical use of 24 hour ambulatory blood pressure variability indices derived from 24-hour ambulatory blood pressure monitoring (ABPM) (JCS 2010): digest version. Circ J. 2012;76(2):508–19.

41. Lodhi HA, Peri-Okonny PA, Schesing K, et al. Usefulness of blood pressure variability indices derived from 24-hour ambulatory blood pressure monitoring in detecting autonomic failure. J Am Heart Assoc. 2019;8(7):e010161.

42. Spudich S, Nath A. Nervous system consequences of COVID-19. Am Heart Assoc. 2019;8(7): e010161.

43. Goldstein DS. Principles of Autonomic Medicine. https://neuroscience.nih.gov/publications/Principles%20of%20Autonomic%20Medicine%20%283rd%29.pdf. Accessed 1 Nov 2022.

44. Goldstein DS. The extended autonomic system, dyshomeostasis, and COVID-19. Clin Auton Res: Off J Clin Auton Res Soc. 2020;30(4):299–315.

45. Novak P. Post-COVID-19 syndrome associated with orthostatic cerebral hyperperfusion syndrome, small fiber neuropathy and benefit of immunomodulation: a case report. eNeurologicalSci. 2020;2:100276.

46. Lamotte G, Benarroch EE, Coon EA. Paroxysmal hypoesthesia and hyperhidrosis with exacerbation after COVID-19 Infection. Clin Auton Res: Off J Clin Auton Res Soc. 2021;31(2):327–9.

47. Mostel Z, Ayat P, Capric V, Trimmingham A, McFarlane SI. Guillain-Barré syndrome in a COVID-19 patient: a case report and review of management strategies. J Med Case Rep. 2021;9(3):198–200.

48. Shouman K, Vanichkachorn G, Cheshire WP, et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clinical autonomic research: official journal of the Clinical Autonomic Research Society. 2021;31(3):385–94. This case series demonstrated that abnormalities on autonomic testing were seen in the majority of patients with persistent symptoms following COVID-19 infection but were mild in most cases. The most common finding was orthostatic intolerance, often without objective hemodynamic abnormalities on testing.

49. Stute NL, Stickford JL, Province VM, Augenchaw MA, Ratchford SM, Stickford ASL. COVID-19 is getting on our nerves: sympathetic neural activity and haemodynamics in young adults recovering from SARS-CoV-2. J Physiol. 2021;599(18):4269–85.
meta-analysis demonstrated that intensive blood pressure-lowering treatment decreases risk for orthostatic hypotension. Orthostatic hypotension, before or in the setting of more intensive blood pressure treatment, should not be viewed as a reason to avoid or de-escalate treatment for hypertension.

66. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387–97.

67. Fanciulli A, Jordan J, Biaggioni I, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res: Off J Clin Auton Res Soc. 2018;28(4):355–62.

68. Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. Hypertension. 1997;30:1062–7.

69. Newman L, O’Connor JD, Romero-Ortuno R, Reilly RB, Kenny RA. Supine hypertension is associated with an impaired cerebral oxygenation response to orthostasis: finding from the Irish longitudinal study on ageing. Hypertension. 2021;78(1):210–9. This study demonstrated that in a large cohort of community-dwelling older adults, supine hypertension was associated with a larger drop and impaired recovery of cerebral oxygenation upon standing when standardized to orthostatic mean arterial pressure.

70. Jordan J, Fanciulli A, Tank J, et al. Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. J Hypertens. 2019;37(8):1541–6.

71. Okamoto LE, Celedonio JE, Smith EC, et al. Local passive heat for the treatment of hypertension in autonomic failure. J Am Heart Assoc. 2021;10(7): e018979. This study demonstrated that local heat therapy effectively lowered overnight blood pressure in patients with autonomic failure and supine hypertension and offers a novel approach to treat this condition.

72. Biaggioni I, Shibao CA, Diedrich A, Muldowney JAS 3rd, Laffer CL, Jordan J. Blood pressure management in afferent baroreflex failure: JACC review topic of the week. J Am Coll Cardiol. 2019;74(23):2939–47.

73. Norcliffe-Kaufmann L, Palma JA, Martinez J, Kaufmann H. Carbidopa for afferent baroreflex failure in familial dysautonomia: a double-blind randomized crossover clinical trial. Hypertension. 2020;76(3):724–31.

74. Vinik AI, Maser RE, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope? Diabet Med. 2011;28(6):643–51.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.